Document Detail


Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease.
MedLine Citation:
PMID:  12353065     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We describe four patients with von Willebrand's disease (VWD) who experienced venous thrombosis after treatment with an intermediate purity factor VIII (FVIII) concentrate (Haemate P3) was used to cover invasive or surgical procedures. Most patients had additional risk factors for venous thromboembolism (VTE) and it is difficult to be certain of the contribution of the concentrate to the VTE. In view of the recognised association between high factor VIII activity (FVIII:C) levels and VTE there is a physiological basis for this complication and it is important to consider this when administering FVIII containing concentrates to VWD patients.
Authors:
M Makris; B Colvin; V Gupta; M L Shields; M P Smith
Related Documents :
2424425 - The proteinase inhibitor complexes (antithrombin iii-thrombin, alpha 2antiplasmin-plasm...
2503935 - Use of a high-purity factor viii concentrate (hemate p) in von willebrand's disease.
7977125 - Hypercoagulable state under low-intensity warfarin anticoagulation assessed with hemost...
20153025 - Influence of anticoagulant therapy with vitamin k antagonists on plasma levels of coagu...
3742925 - The evaluation of minor cervical blunt trauma in the pediatric patient.
20511205 - Migraine with aura with onset in childhood and adolescence: long-term natural history a...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  88     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-10-01     Completed Date:  2003-08-25     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  387-8     Citation Subset:  IM    
Affiliation:
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, UK. michaelmakris@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Factor VIII / adverse effects*,  therapeutic use
Female
Humans
Middle Aged
Risk Factors
Surgical Procedures, Operative / adverse effects
Venous Thrombosis / chemically induced*,  etiology
von Willebrand Diseases / complications*,  therapy
Chemical
Reg. No./Substance:
9001-27-8/Factor VIII
Comments/Corrections
Comment In:
Thromb Haemost. 2002 Sep;88(3):378-9   [PMID:  12353063 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Standardisation of von Willebrand Factor in therapeutic concentrates: calibration of the 1st Interna...
Next Document:  The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein t...